The price of Remdesivir for Indonesia has dropped to IDR 1.5 million per vial

KOMPAS.com – PT To heart Farma Tbk and PT Amarox Pharma Global lowered drug prices remdesivir with a trademark Covifor to IDR 1.5 million per vial.

In previous reports, Kalbe and Amarox announced that they would sell the Covifor drug in Indonesia for Rp 3 million per vial.

However, after hearing suggestions from the government, health workers and patients, it was finally decided that there would be an adjustment in prices.

Also read: Especially for severe Covid-19 patients, Remdesivir for Indonesia is sold for IDR 3 million

In the official statement received by Kalbe Farma Kompas.com, Saturday (3/10/2020), this price adjustment is in line with Kalbe and Amarox’s commitment to support the government in overcoming the Covid-19 pandemic and considering that more patients will benefit from the Covifor drug to cure Covid-19.

“Hetero is aware of the widespread impact of the Covid-19 pandemic, especially related to the cost burden for the government and patients. So Hetero is providing more support and providing a special Covifor price for Indonesia,” said Sandeep Sur, Country Manager of PT Amarox Global Pharma.

President Director of PT Kalbe Farma Tbk, Vidjongtius added, the adjustment of Covifor’s drug prices after considering several current conditions.

Starting from the development of the Covid-19 case in Indonesia, the need for remdesivir drug treatment for Covid-19 is large, and especially input from the government, health workers and patients.

“After a joint discussion between Kalbe, Hetero India and Amarox, we agreed to provide a special selling price for Covifor,” added Vidjongtius.

“This is the commitment of Kalbe and Amarox to support the government in overcoming the Covid-19 pandemic,” continued Vidjongtius.

Also read: 8 Facts about Remdesivir for Indonesia, from Price to Side Effects

To note, Covifor is a remdesivir drug produced by the leading pharmaceutical company Hetero India, imported by Amarox, and marketed and distributed by Kalbe.

Covifor is the first remedial drug to be approved as an emergency use authorization (UEA) or an emergency use authority by the Food and Drug Administration (BPOM).

The drug remdesivir is only intended for the treatment of patients with Covid-19 disease that has been confirmed by the laboratory, especially for adults or adolescents (aged 12 years and over with a minimum body weight of 40 kilograms) who are hospitalized with severe conditions.

Therefore, Covifor products are not sold freely and are only used in hospitals with a doctor’s recommendation and supervision.

– .